Windtree Therapeutics, Inc.
Income Statement
| Line Item | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $158.0K | $40.0K | $304.0K | $229.0K | $1.1M | $204.0K | $102.0K | $17.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $3.4M | $3.3M | $2.4M | $2.2M | $2.9M | $3.1M | $2.4M | $3.1M |
| SG&A Expense | $3.2M | $3.4M | $2.8M | $1.5M | $1.2M | $1.9M | $1.2M | $1.7M |
| Operating Income | $-6.5M | $-6.7M | $-4.9M | $-3.5M | $-3.0M | $-4.8M | $-3.5M | $-4.8M |
| Operating Margin | -4,110.8% | -16,642.5% | -1,595.7% | -1,514.4% | -288.9% | -2,372.5% | -3,429.4% | -28,200.0% |
| Interest Expense | $117.0K | $136.0K | $767.0K | $460.0K | $92.0K | $90.0K | $-15.0K | $652.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-6.4M | $-6.5M | $-9.0M | $-3.9M | $-3.1M | $-4.5M | $2.5M | $-5.4M |
| Net Margin | -4,074.1% | -16,342.5% | -2,974.3% | -1,714.8% | -290.4% | -2,211.8% | 2,424.5% | -32,017.6% |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.04 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.03 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.04 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.03 |
| Shares Outstanding (Basic) | 2.70B | 2.70B | 604.0M | 1.27B | 1.26B | 1.08B | 808.1M | 244.9M |
| Shares Outstanding (Diluted) | 2.70B | 2.70B | 604.0M | 1.27B | 1.26B | 1.08B | 853.4M | 244.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |